Group 1 - The core point of the news is that Xuan Bamboo Biotech (2575.HK) has seen a significant stock price increase, rising 35.16% to HKD 61.5, reaching a new high since its IPO, with a market capitalization approaching HKD 32 billion [1] - The stock has increased by 430.17% from its IPO price of HKD 11.6 since its listing on October 15 [1] - The company presented interim analysis results of the BRIGHT-3 clinical trial at the 2025 European Society for Medical Oncology (ESMO), showcasing the efficacy of palbociclib combined with aromatase inhibitors in treating HR+/HER2- advanced breast cancer [1] Group 2 - The interim analysis indicates that the palbociclib regimen reduces the risk of disease progression or death by 47% compared to placebo combined with endocrine therapy, with a notable 64% reduction in patients with liver metastases [2] - In the intention-to-treat population, the overall response rate (ORR) for the palbociclib group reached 63.5%, significantly higher than the control group's 42.5% [2] - Common adverse events associated with the palbociclib regimen are manageable and primarily of grade 1-2 severity, including diarrhea and neutropenia, indicating an overall controllable safety profile [2]
港股异动丨轩竹生物逆势大涨35%创新高 上市六日股价较发行价已累涨超4倍 市值超300亿
Ge Long Hui·2025-10-22 08:07